EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Mironid Announces Additional Non-Dilutive Funding Through an Early Stage Award from Innovate UK’s Biomedical Catalyst 2016
Glasgow, Scotland, 30th January 2017: Mironid® Limited, a leader in cell signalling-directed drug discovery, is delighted to start the New Year by initiating a £606K
Sirakoss Announces Two New Patents Granted by the United States Patent and Trademark Office
Aberdeen, United Kingdom, January 10, 2017 – SIRAKOSS Ltd., a UK-based medical device company developing innovative bone grafting solutions for the $3 billion global orthopaedic
Eternygen GmbH Closes € 8.0 million (US$ 8.3m) Series A Financing Led by Epidarex Capital
Berlin, Germany, 09 January 2017 – Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3)
Mironid is Delighted to Announce that Dr. George Muller Has Joined Our Scientific Advisory Board
Mironid’s ShoLo® and LoAc® programmes benefit from a close association with Dr George Muller as a key medicinal chemistry and experienced drug development advisor. George
Apellis Announces FDA Fast Track Designation for APL-2 in PNH
C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience
Mironid and University of Sheffield Collaborate on Kidney Disease Drug Discovery
Glasgow, Scotland, and Sheffield, UK, 12th December 2016 – Mironid Ltd, a leader in cell signalling-directed drug development, and the University of Sheffield, announced today
Mironid is Delighted to Announce that Prof Albert Ong Has Joined Our Scientific Advisory Board
Mironid is delighted to announce that Prof Albert Ong DM MA FRCP, Professor of Renal Medicine, Department of Infection Immunity & Cardiovascular Disease, University of
Apellis Reports Positive Interim Results from Phase Ib Clinical Trials of APL-2 in PNH
Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim